Growth Hormone Secretagogues: Complete Research Guide
Growth hormone secretagogues (GHS) are a class of peptides that stimulate the body’s own growth hormone (GH) production rather than providing exogenous GH directly. This makes them valuable research tools for studying GH physiology.
How Secretagogues Work
GH secretagogues stimulate the pituitary gland to release growth hormone through two main pathways: GHRH (growth hormone-releasing hormone) receptor activation and GHS-R (ghrelin receptor) activation. Different secretagogues target different pathways, allowing researchers to study specific aspects of GH regulation.
GHRH Analogs
CJC-1295 (no DAC) — Also known as Mod GRF 1-29, this modified GHRH analog stimulates GH release by directly activating GHRH receptors. It amplifies natural GH pulses without disrupting the pulsatile release pattern. Tesamorelin — An FDA-studied GHRH analog with applications in visceral adiposity research.
Ghrelin Mimetics
Ipamorelin — A highly selective GHS-R agonist that stimulates GH release without significantly affecting cortisol or prolactin. This selectivity makes it valuable for studying GH-specific effects.
Combination Protocols
Research frequently combines GHRH analogs with ghrelin mimetics for synergistic GH release. The CJC-1295/ipamorelin combination is one of the most studied pairings, as they activate complementary pathways for amplified GH secretion.
Secretagogues vs Direct GH
Key advantages of secretagogues over exogenous GH include: maintenance of natural pulsatile release patterns, feedback regulation remains intact, lower risk of supraphysiological GH levels, and potentially better long-term safety profiles in research models.
Related Articles: Ipamorelin vs Sermorelin | CJC-1295 DAC vs No DAC | Peptides vs HGH
For research use only. Browse GH secretagogue peptides at Proxiva Labs with verified COAs.